• Oncoinvent reported publication of normal-tissue dosimetry data from Phase 1 Radspherin studies in ovarian and colorectal cancer.
• Final clinical results from the Phase 1 studies were already presented previously; the new update covers dosimetry findings now published.
• The analysis indicated radiation exposure to healthy organs stayed below levels typically linked to toxicity risk, supporting the product’s safety profile.
• The publication supports continued development of Radspherin as a post-surgery treatment approach for peritoneal metastases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncoinvent ASA published the original content used to generate this news brief via Cision (Ref. ID: 202608110100BITN____UKPR__EN_20260810-BIT-6144-0) on August 11, 2026, and is solely responsible for the information contained therein.